Cross-Sector entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention CSL Behring, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Octapharma, all published on February 20, 2026.
1 verified story tracked
Last mentioned: Feb 20, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention CSL Behring, the most common co-covered peer. We currently track 1 Cross-Sector story that mention Octapharma, all published on February 20, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Octapharma. Shared-story counts are live from our verified record — not editorial picks.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by massive investments in plasma collection infrastructure and rising demand for primary immunodeficiency treatments. This growth reflects a stabilization of the supply chain following pandemic-era disruptions and a strategic shift toward subcutaneous delivery methods.
